DuPont Merck
Executive Summary
First year sales exceed projections by more than 10%, to $780 mil. Worldwide pharmaceutical sales contributed $634 mil., while the radiopharmaeuticals division reported revenues of $146 mil. The company also said it generated "respectable profits," despite costs involved in expanding European operations. Two "major" research compounds are "well into" Phase III clinicals -- Aviva (linopirdine) for treatment of Alzheimer's disease, and Avastar, (DUP-753) an antihypertensive being codeveloped with Merck.